Phase 4 N=3,298 Stress Ulcer Prophylaxis in the Intensive Care Unit
Gastrointestinal Bleeding · Stress Ulcers
Primary: Mortality — 510; 499 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=124 Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
Gastrointestinal Hemorrhage · Clostridium Difficile Colitis
Primary: Number of Subjects With GI Bleeding — 1; 1 participants
Phase 3 N=311 Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
Stress Ulcer Prophylaxis
Primary: The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase — 2.7; 4.6 % of participants — p=0.393
Phase 2 N=165 Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Peptic Ulcer
Primary: Recurrent Peptic Ulcer — 1; 9 participants
N/A N=144 Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Pressure Ulcers · Spinal Cord Injuries
Primary: Percent of Possible Self-Reported Skin Care Behaviors — 73.8; 74.1; 83.5; 79.5 % of Possible Self-Reported Behaviors
N/A N=63 Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]
Acute Stress Ulcer and Acute Gastric Mucosal Lesions
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 0 participants
N/A N=101 Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants With Ulcer Recurrence — 1; 7 participants
Phase 4 N=40 Ulcer Prevention Study in Post Gastric Bypass Patients
Marginal Ulcers
Primary: Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia. — 17; 13 participants
N/A N=1,059 Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients
Critically Ill
Primary: Percentage of Prescribed Calories From Energy — 32; 34.2; 43.6; 33.6 percentage of prescription
Phase 4 N=178 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants in Whom Peptic Ulcer Was Healed — 66; 66 participants
Phase 3 N=222 High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
Bleeding Peptic Ulcer
Primary: Rate of Clinically Significant Rebleeding Within 72 Hours — 107; 101; 1; 6 participants
Phase 3 N=305 Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients
Critically Ill
Primary: Documented Infection Rate — 58; 41 Infections
N/A N=8,616 Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)
Erosive Gastroesophageal Reflux Disease · Non-Erosive Reflux Disease
Primary: Assessment of the Severity of Sleep Disturbances — 13.8; 77.4; 38.2; 20.0 percentage of participants
Phase 3 N=330 Pressure Ulcer Prevention in Ventilated Patients Using Two Repositioning Regimens
Pressure Ulcers
Primary: Incidence of Pressure Ulcer (PU) Grade ≥ II — 22; 17 participants
Phase 3 N=764 A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
Gastrointestinal Hemorrhage
Primary: Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo — 22; 40 Participants
N/A N=1,120 Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]
Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 35 participants
N/A N=228 Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
Peptic Ulcer
Primary: Number of Participants With Healed Peptic Ulcer — 106; 101 participants
N/A N=220,306 Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program
Proton Pump Inhibitors
Primary: PPI Prescribing (H1) — 73.69; 72.66 percentage of days on PPI
Phase 3 N=500 Supplemental Enteral Protein in Critical Illness
Nutrition Disorder · Trauma · Critical Illness
Primary: Serum Concentrations of Transthyretin at 3 Weeks After Injury. — 18.1; 18.9 mg/dl
N/A N=117 SUPER Study (Substance Use and PTSD Treatment Effectiveness Research Study)
Substance Use Disorders · Posttraumatic Stress Disorder
Primary: Severity of Alcohol Use (ASI Alcohol Composite Scores) — .259; .225; .169; .152 units on a scale — p=> .05
Phase 2 N=247 Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
N/A N=3,343 Silk-Like Bed Linens for Prevention of Unit-Acquired Ulcers
Pressure Ulcer
Primary: Rate of Development of Unit-acquired Pressure Ulcers — 45; 42 Participants
Phase 4 N=123 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
Helicobacter Pylori Infection
Primary: Urea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped. — 1; 3; 1; 0 participants
Phase 2 N=400 LIPS-A: Lung Injury Prevention Study With Aspirin
Acute Respiratory Distress Syndrome
Primary: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days — 20; 17 participants — p=0.53
N/A N=3,366 Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin
Gastric or Duodenal Ulcers
Primary: Frequency of Adverse Drug Reactions — 1; 1; 1; 1 participants
Phase 4 N=64 Symptom Control Satisfaction With Proton Pump Inhibitor Regimen
Heartburn
Primary: Symptom Frequency and Severity/Distress Scores From Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) (Overall) — 8.5; 5.2; 2.2; 1.0 score on a scale
Phase 2 N=314 Strategies To Prevent Pneumonia 2 (SToPP2)
Infections, Hospital · Ventilator-Associated Pneumonia · Mechanical Ventilation Complication
Primary: Development of VAP (Clinical Pulmonary Infection Score) — 4.13; 4.45 units on a scale — p=0.1763
Phase 3 N=471 Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Primary: Cumulative Recurrent Rates of Gastric or Duodenal Ulcers — 2.8; 1.4; 21.7 Events/100 participants/24 weeks — p=<0.001
Phase 3 N=1,950 Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Post-ERCP Pancreatitis
Primary: The Proportion of Subjects in Each Study Group With Post-ERCP Pancreatitis — 145; 110; 137; 90 Participants
N/A N=60 Proton Pump Inhibitors and Dysbiosis in Cirrhosis
Cirrhosis · Healthy
Primary: Number of Patients With Overgrowth of Oral Microbiota in Their Stool After PPI Therapy Withdrawal or Initiation — 45; 15 Participants